I guess this is a philosophical debate on how medical treatments make it to market. Either through public institutions of private entities. I see both approaches working but that's probably for a different forum. lolMy take:
University of Michigan is a research institution interested in generating good, interesting data to be published in well-reviewed articles which end up getting cited by many others. Productization is vastly a secondary concern -- this is a detriment to patients in terms of timing but means the data being generated is implicitly less biased.
Neuromod is a heavily venture capital backed company burning up their runway who basically have to get something on the market ASAP or else the lights go out and they crash and burn like 95% of startups. They claim to have performed a large, convincing study -- and I have no reason to disbelieve them -- but so far this has not been published anywhere.
Basically, University of Michigan seems more transparency oriented (published all their protocols and have even worked a bit in email with those of us attempting to DIY their stuff) whereas Neuromod seems a lot more flash-and-cash oriented.
I don't have any particular mistrust of Neuromod, but like every other bit of vaporware out there -- I'll believe it's a thing when it is.
I know for a fact that treatments created through universities are incredibly lucrative. I don't assume that because something is developed by a university it is any more altruistic than a private group. AKA Michigan, Minnesota or Neuromod, etc... It's not lucrative for the students doing the work though.
Thanks for your opinions all.